Medicare is putting restrictions on coverage for Biogen’s Alzheimer’s drug, Aduhelm. It’s like having a sweet treat that you can only share with a select few friends. Medicare will only cover the drug for patients involved in clinical trials, as part of their final coverage policy. Just like how you might limit your special stash of candies to only a few people. This decision follows the controversial approval of Aduhelm by the U.S. Food and Drug Administration (FDA). It has caused debate among experts, with concerns about its effectiveness and high cost. By limiting coverage to clinical trial patients, Medicare is taking a cautious approach to ensure that the drug is being used in a controlled and monitored environment. This move may also help generate more data about the drug’s real-world impact. If you want to learn more about the specifics of this coverage policy or the ongoing debates surrounding Aduhelm, dive into the full article!
